Today, on 11th April 2025, Cipla Pharmaceuticals, among other pharmaceutical companies, CIPLA Share Price experienced a 5% boost in its share prices. This results from the US administration’s decision to suspend additional tariffs on pharmaceutical companies for 90 days while retaining the 10% beeline tariffs.
The relief, however, will not last long as the US president, Donald Trump, stated that pharmaceutical companies are being looked at as a different category and that the US administration will impose the revised tariffs soon. He warned the companies of the never-before-seen tariffs.
Cipla’s Share Price in Today’s Market
Today, Cipla’s shares opened to the market at Rs.1,460 and are currently up by 2% compared to the previous close of Rs. 1,415.60. At 11:30 a.m., Cipla’s share price was 1,452.55, nearly 2.6% higher than its previous close. According to the reports and estimates on Money Control, the current market capitalization shows 117,213 cores; the UC Limit is 1,557.15, and the LC Limit is 1,274.05.
Company Financials
Based on the Q3 results of the fiscal year 2024-25, Cipla reported revenue from operations as Rs. 7,073 crore, up 7% year-on-year from Rs. 6,604 crore. Its net profit improved by 49%, earning Rs. q,571 crore, compared to Rs. 1,056 crore in Q3 FY24. The company’s EBITDA Margin stood at 28.1%, an increase from 26.3% in the same quarter last year. Cipla reported its earnings per share to be Rs. 19.45.
Cipla’s segment-wise performance:
- Revenue grew by 10% in India. Cipla recorded Rs. 3,146 crore and named strong demand in respiratory and urology therapies as the cause.
- Revenue declined by 1% year-on-year in North America. Cipla minted $226 million.
- Emerging Markets & Europe reported 20% year-on-year revenue growth.
- Revenue increased by 21% in South Africa (ZAR)
Recent News About Cipla
- Cipla and Formosa Pharmaceuticals signed an exclusive licensing deal in March 2025 to commercialize APP13007.
- Umang Vohra, the CEO of Cipla, responded to worries about possible US tariffs on pharmaceutical imports in February 2025.
- He warned against basing large infrastructure investments only on short-term trade policies. He underlined that such tariffs shouldn’t control the commercial plans of Indian pharmaceutical companies.
Cipla Share Price Target
According to the latest calculations from experts on Trendlyne, Cipla Ltd. has an average target of 1707.30. The consensus estimate represents an upside of 17.55% from the last price of 1452.35.
Should You Buy, Sell, Or Hold?
Most analysts on Trendlyne support buying Cipla’s shares. On Moneycontrol, 46% of experts suggest buying, 22% recommend holding, and 3% suggest selling the shares.
Before investing in Cipla, consider its long-term performance and consult your analyst to make the perfect move.
